Another China vaccine mass production soon...

China-produced vaccines await approval by EU and WHO, will be 'major boon to the world'

The European Medicines Agency (EMA) has started a rolling review of China's Sinovac COVID-19 vaccine, the EU's top drug regulator announced Tuesday, and experts said that once the vaccine is approved, China will further fulfill its international responsibilities as a major power and provide support to the international community in the pandemic fight.

Sinovac and another China-produced COVID-19 jab, Sinopharm, are also under WHO assessment for emergency use, and results are anticipated in a week.

The EMA said the decision on whether Sinovac can be marketed in Europe will be based on preliminary results from laboratory and clinical studies.

According to the EMA, a rolling review is to speed up the assessment of a promising medicine during a public health emergency, allowing data to be reviewed as they become available from ongoing studies. A specific timeframe for the review is not provided, but the EMA said the process should "take less time than normal."

Sources at Sinovac told the Global Times on Wednesday that since there are many COVID-19 vaccines awaiting EMA approval, the process is not expected to be completed soon. The previous four vaccines took two to three months to be approved after rolling reviews began.

The agency has ongoing rolling reviews of three other vaccines, Sputnik, CureVac and Novavax.

The EMA has previously approved four COVID-19 vaccines, developed by BioNTech and Pfizer, Moderna, AstraZeneca and Janssen. If approved, the Sinovac vaccine will be the first non-Western COVID-19 vaccine to receive marketing authorization in the EU.

In April, Sinopharm's COVID-19 vaccine received a Good Manufacturing Practice (GMP) certificate from Hungarian authorities, the first Chinese COVID-19 vaccine to receive such a certificate from an EU country and a step forward for Chinese vaccines to become a global public good.

Vaccine experts pointed out that the issuance greatly enhances the competitiveness of China-produced vaccines in Europe and the confidence of smaller European countries in Chinese vaccines given the uneven distribution of vaccines in Europe.

"With reference to this certificate, it is also more likely that the EMA will approve the Chinese vaccine market license more quickly," Tao Lina, a Shanghai-based vaccine expert told the Global Times on Wednesday.

Sinovac and Sinopharm are also under WHO assessment for emergency use, and the results are anticipated in early May.

Cont...


## https://www.globaltimes.cn/page/202105/1222712.shtml

Another China vaccine mass production soon...

China-produced vaccines await approval by EU and WHO, will be 'major boon to the world'

The European Medicines Agency (EMA) has started a rolling review of China's Sinovac COVID-19 vaccine, the EU's top drug regulator announced Tuesday, and experts said that once the vaccine is approved, China will further fulfill its international responsibilities as a major power and provide support to the international community in the pandemic fight.

Sinovac and another China-produced COVID-19 jab, Sinopharm, are also under WHO assessment for emergency use, and results are anticipated in a week.

The EMA said the decision on whether Sinovac can be marketed in Europe will be based on preliminary results from laboratory and clinical studies.

According to the EMA, a rolling review is to speed up the assessment of a promising medicine during a public health emergency, allowing data to be reviewed as they become available from ongoing studies. A specific timeframe for the review is not provided, but the EMA said the process should "take less time than normal."

Sources at Sinovac told the Global Times on Wednesday that since there are many COVID-19 vaccines awaiting EMA approval, the process is not expected to be completed soon. The previous four vaccines took two to three months to be approved after rolling reviews began.

The agency has ongoing rolling reviews of three other vaccines, Sputnik, CureVac and Novavax.

The EMA has previously approved four COVID-19 vaccines, developed by BioNTech and Pfizer, Moderna, AstraZeneca and Janssen. If approved, the Sinovac vaccine will be the first non-Western COVID-19 vaccine to receive marketing authorization in the EU.

In April, Sinopharm's COVID-19 vaccine received a Good Manufacturing Practice (GMP) certificate from Hungarian authorities, the first Chinese COVID-19 vaccine to receive such a certificate from an EU country and a step forward for Chinese vaccines to become a global public good.

Vaccine experts pointed out that the issuance greatly enhances the competitiveness of China-produced vaccines in Europe and the confidence of smaller European countries in Chinese vaccines given the uneven distribution of vaccines in Europe.

"With reference to this certificate, it is also more likely that the EMA will approve the Chinese vaccine market license more quickly," Tao Lina, a Shanghai-based vaccine expert told the Global Times on Wednesday.

Sinovac and Sinopharm are also under WHO assessment for emergency use, and the results are anticipated in early May.

Cont...


## https://www.globaltimes.cn/page/202105/1222712.shtml

Finally...finally mass production to worldwide...

CHEERS...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Finally...finally mass production to worldwide...

CHEERS...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Finally...finally mass production to worldwide...

CHEERS...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Finally...finally mass production to worldwide...

CHEERS...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Finally...finally mass production to worldwide...

CHEERS...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Finally...finally mass production to worldwide...


CHEERS...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Finally...finally mass production to worldwide...

CHEERS...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Finally...finally mass production to worldwide...


Cheers...

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

07 May 2021 11:34PM (Updated: 08 May 2021 12:11AM)

GENEVA: The World Health Organization announced on Friday (May 7) it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

"This afternoon, WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," the UN health agency's director-general Tedros Adhanom Ghebreyesus told a news conference.

Tedros also said that a separate expert panel has recommended two doses of Sinopharm vaccine for those aged 18 and above.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

The decision to approve Sinopharm's vaccine was taken by WHO's technical advisory group, which began meeting on Apr 26 to review the latest clinical data as well as Sinopharm's manufacturing practices.

A separate group of WHO experts, the Strategic Advisory Group of Experts (SAGE), voiced concern this week over data provided by Sinopharm on the risk of serious side-effects in some patients, but was confident in the vaccine's ability to prevent disease, according to a document reviewed by Reuters.

SAGE found an efficacy of 78.1 per cent after two doses in multi-country Phase III clinical trials, according to the document. The vaccine's developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group, had announced an efficacy of 79.34 per cent.

The WHO has said it could reach a decision on China's other main COVID-19 vaccine, made by Sinovac Biotech, as soon as next week. The technical experts reviewed it on Wednesday.

China has deployed around 65 million doses of the Sinopharm vaccine and more than 200 million doses of the Sinovac shot. Both have been exported to many countries, particularly in Latin America, Asia and Africa, many of which have had difficulty securing supplies of vaccines developed in the West.


## https://www.channelnewsasia.com/news/asia/covid-19-sinopharm-who-emergency-approval-first-china-vaccine-14764686

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Great...Great improvement...

U.S. Infections Ease; U.K. Deaths Slow to Two: Virus Update

(Bloomberg News / May 10, 2021, 7:07 AM GMT+8)


U.S. deaths from Covid-19 have been undercounted, President Joe Biden’s top medical adviser said, with the nationwide toll approaching 582,000. New cases in the U.S. dropped over the past week to the slowest pace since the end of September. Hospitalizations dipped to a seven-month low.

With more than a third of its adult population now fully vaccinated, the U.K. reported just two virus deaths on Sunday. The European Union hasn’t renewed its order for the AstraZeneca Plc vaccine beyond June.


## https://www.bloomberg.com/news/articles/2021-05-09/u-s-infections-ease-u-k-deaths-slow-to-two-virus-update?srnd=premium-asia

Seem like you never check the history post....


Kesian...kesian...


Are you start nervous!!!......



wkwkwk...kekeke...hehehe...


Posted by Biliskecil > May 9, 2021 10:49 PM | Report Abuse 

Keyman how's your glove!? Hope you cleared your position using the dead cat bounce

What was the past 10 year average PE ???...(just using simple ratio 1st)...

Is it range 16 ~ 18 time PE !!!...

Don't stringy lahhh....

All sifu here just give some "PROPER SENSE" guidance to Keyman188 lahhh...

Aiyo...simple lahh..

Can you do Keyman188 simple favour...

Please ring to EPF...ask them stop accumulating 1st then let the share price further downhill !!!...

Keyman188 guess a lot of members here also waiting...


Can ???..........



Posted by Garmadon > May 9, 2021 8:56 PM | Report Abuse

still queing at 2.06... please drop more for me to collect

But you omitted to use other "Sigma" to evaluate upcoming "Real Intrinsic Value"...

Keyman188 saw a lot of new face started to join in this battle liao...

古语有云 : 瘦田没人耕 耕开有人争

Great...Great...


Really good sign for Genting...


Right now more & more realized where is the GEM...what is real GEM...


wkwkwk...kekeke...hehehe...

After 25 Years, ESPRIT Will Be Closing Down ALL Malaysian Stores By End Of June

## https://worldofbuzz.com/after-25-years-esprit-will-be-closing-down-all-malaysian-stores-by-end-of-june/



Let the newbies refresh & recall the well-know garment chain news...

Have you visit Metrojaya before !!!...

Nowadays...apa apa company also said wanted to join the glove bandwagon...

Same pattern with last 10 years...

apa apa company also said wanted to join property development...

Same pattern with last 3 years...

apa apa entrepreneur also said wanted to open bubble tea franchise...


Malaysia memang boleh...

Not all the stock necessary to use TA...

Sometime TA can kill the market...

Do you know the story between OSK & PJD !!!...

Don't let the share price cheated you...